Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial (vol 19, pg 510, 2018)

被引：0
|
作者：
Maio, M.
Lewis, K.
Demidov, L.
机构：
来源：
LANCET ONCOLOGY | 2018年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E184 / E184
页数：1
相关论文
共 50 条
  • [1] Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Maio, Michele
    Lewis, Karl
    Demidov, Lev
    Mandala, Mario
    Bondarenko, Igor
    Ascierto, Paolo A.
    Herbert, Christopher
    Mackiewicz, Andrzej
    Rutkowski, Piotr
    Guminski, Alexander
    Goodman, Grant R.
    Simmons, Brian
    Ye, Chenglin
    Yan, Yibing
    Schadendorf, Dirk
    LANCET ONCOLOGY, 2018, 19 (04): : 510 - 520
  • [2] BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+melanoma at high risk for recurrence
    Lewis, K.
    Maio, M.
    Demidov, L.
    Mandala, M.
    Ascierto, P. A.
    Herbert, C.
    Mackiewicz, A.
    Rutkowski, P.
    Guminski, A.
    Goodman, G.
    Simmons, B.
    Ye, C.
    Yan, Y.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
    Gutzmer, Ralf
    Stroyakovskiy, Daniil
    Gogas, Helen
    Robert, Caroline
    Lewis, Karl
    Protsenko, Svetlana
    Pereira, Rodrigo P.
    Eigentler, Thomas
    Rutkowski, Piotr
    Demidov, Lev
    Manikhas, Georgy Moiseevich
    Yan, Yibing
    Huang, Kuan-Chieh
    Uyei, Anne
    McNally, Virginia
    McArthur, Grant A.
    Ascierto, Paolo A.
    LANCET, 2020, 395 (10240): : 1835 - 1844
  • [4] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (vol 395, pg 1835, 2020)
    Gutzmer, R.
    Stroyakovskiy, D.
    Gogas, H.
    Robert, Caroline
    Lewis, Karl
    Protsenko, Svetlana
    Pereira, Rodrigo P.
    Eigentler, Thomas
    Rutkowski, Piotr
    Demidov, Lev
    Manikhas, Georgy Moiseevich
    Yan, Yibing
    Huang, Kuan-Chieh
    Uyei, Anne
    McNally, Virginia
    McArthur, Grant A.
    Ascierto, Paolo A.
    LANCET, 2020, 396 (10249): : 466 - 466
  • [5] coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
    Paolo A Ascierto
    Grant A. McArthur
    Brigitte Dréno
    James Larkin
    Gabriella Liszkay
    Michele Maio
    Mario Mandala
    Lev Demidov
    Daniil Stroyakovskiy
    Luc Thomas
    Luis de la Cruz-Merino
    Victoria Atkinson
    Caroline Dutriaux
    Claus Garbe
    Ilsung Chang
    Stephen P. Hack
    Antoni Ribas
    Journal of Translational Medicine, 13 (Suppl 1)
  • [6] BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419).
    Lewis, Karl D.
    Maio, Michele
    Mandala, Mario
    Nelson, Betty J.
    Goodman, Grant R.
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020)
    Khanna, D.
    Lin, C. J. F.
    Furst, D. E.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E75 - E75
  • [8] Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020)
    Khanna, Dinesh
    Lin, Celia J. F.
    Furst, Daniel E.
    Goldin, Jonathan
    Kim, Grace
    Kuwana, Masataka
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Distler, Oliver
    Shima, Yoshihito
    van Laar, Jacob M.
    Spotswood, Helen
    Wagner, Bridget
    Siegel, Jeffrey
    Denton, Christopher P.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : E29 - E29
  • [9] Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
    McArthur, Grant A.
    Chapman, Paul B.
    Robert, Caroline
    Larkin, James
    Haanen, John B.
    Dummer, Reinhard
    Ribas, Antoni
    Hogg, David
    Hamid, Omid
    Ascierto, Paolo A.
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    O'Day, Stephen J.
    Kirkwood, John M.
    Eggermont, Alexander M.
    Dreno, Brigitte
    Sosman, Jefferey A.
    Flaherty, Keith T.
    Yin, Ming
    Caro, Ivor
    Cheng, Suzanne
    Trunzer, Kerstin
    Hauschild, Axel
    LANCET ONCOLOGY, 2014, 15 (03): : 323 - 332
  • [10] MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
    Dreno, Brigitte
    Thompson, John F.
    Smithers, Bernard Mark
    Santinami, Mario
    Jouary, Thomas
    Gutzmer, Ralf
    Levchenko, Evgeny
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Korovin, Sergii
    Drucis, Kamil
    Grange, Florent
    Machet, Laurent
    Hersey, Peter
    Krajsova, Ivana
    Testori, Alessandro
    Conry, Robert
    Guillot, Bernard
    Kruit, Wim H. J.
    Demidov, Lev
    Thompson, John A.
    Bondarenko, Igor
    Jaroszek, Jaroslaw
    Puig, Susana
    Cinat, Gabriela
    Hauschild, Axel
    Goeman, Jelle J.
    van Houwelingen, Hans C.
    Ulloa-Montoya, Fernando
    Callegaro, Andrea
    Dizier, Benjamin
    Spiessens, Bart
    Debois, Muriel
    Brichard, Vincent G.
    Louahed, Jamila
    Therasse, Patrick
    Debruyne, Channa
    Kirkwood, John M.
    LANCET ONCOLOGY, 2018, 19 (07): : 916 - 929
12345